Diquafosol (tetrasodium)

Diquafosol tetrasodium is a P2Y2 receptor agonist that stimulates fluid and mucin secretion on the ocular surface, as a topical treatment of dry eye disease.

Product Specifications

CAS Number

[211427-08-6]

Product Name Alternative

INS365

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

P2Y Receptor

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Concentration

10mM

Purity

99.0

Solubility

DMSO : 1 mg/mL (ultrasonic) |H2O : 100 mg/mL (ultrasonic)

Smiles

O[C@H]1[C@@H](O)[C@H](N(C(N2)=O)C=CC2=O)O[C@@H]1COP(OP(OP(OP(OC[C@@H]3[C@@H](O)[C@@H](O)[C@H](N4C(NC(C=C4)=O)=O)O3)(O[Na])=O)(O[Na])=O)(O[Na])=O)(O[Na])=O

Molecular Formula

C18H22N4Na4O23P4

Molecular Weight

878.23

Precautions

H302, H315, H319, H335

References & Citations

[1]Lee JH, et al. Comparison of cytotoxicities and wound healing effects of diquafosol tetrasodium and hyaluronic acid on human corneal epithelial cells. Korean J Physiol Pharmacol. 2017 Mar;21 (2) :189-195.|[2]Fujihara T, et al. Improvement of corneal barrier function by the P2Y (2) agonist INS365 in a rat dry eye model. Invest Ophthalmol Vis Sci. 2001 Jan;42 (1) :96-100.|[3]Fujihara T, et al. INS365 suppresses loss of corneal epithelial integrity by secretion of mucin-like glycoprotein in a rabbit short-term dry eye model. J Ocul Pharmacol Ther. 2002 Aug;18 (4) :363-70.